Wrapsa believes in investing in the future

posted on
Wrapsa believes in investing in the future

South Africa’s biggest pharmaceutical contract manufacturer and packaging company, Wrapsa, have spent millions to ensure continuous upgrading of its facilities, in line with its policy to invest in infrastructure to ensure accreditation in order to retain its position in the local market.

Wrapsa was established in 1983 by Nardus Alberts, who took the strategic decision from the start to only do contract manufacturing and not manufacture his own brands. He was also very serious about ploughing profit back into the company.

“Since 2007 we have spent R80 million to upgrade our manufacturing plant and we are planning a second phase for 2017. Within the next eighteen months, we want to extend Wrapsa’s manufacturing facilities to increase our tablet manufacturing ability in order to serve new clients,” says Alberts.

Wrapsa’s aim is to give product owners a competitive edge, because the exchange rate makes local manufacturing a cheaper and more flexible option for local and international clients.

According to Alberts, Wrapsa’s variety of services and infrastructure, created to suit clients’ needs, as well as its ability to handle many kinds of low volumes, distinguishes it from its competitors. The key staff members also have more than 100 years’ experience amongst them.

Various high profile companies use Wrapsa for the manufacture of liquids, creams, ointments, gels, tablets, granules and tooth paste. The company also has an aerosol section, which has received the highest award in one of the categories of the Puregas Partnership Awards over the past six years. 

Wrapsa also offers specialised services that include the registration of medicine, validation assistance and the acceptance of raw materials and packaging components on consignment basis. On the packaging side, it offers blister and strip packaging, sachet filling, shrink wrapping, skin and blister packaging and packaging for tablets and capsules. The company also has a health supplement and packaging plant with ISO 22000:2005 accreditation.

“We have the experience, ability and equipment to manufacture all kinds of pharmaceutical products and Wrapsa always complies with quality objectives, on time and without complaints. As we have so many high profile clients, our manufacturing standards are always under scrutiny and our plant is subjected to inspections by clients, as well as the Medicines Control Council,” says Alberts.

Wrapsa’s quality systems comply with the criteria set by the SABS for its ISO grading and is operated in line with required GMP (Good Manufacturing Practice).

Categories: Customer Releases, News, Press Releases | Tags: Wrapsa , Pharmaceutical , Investments , Manufacturing | Comments: (0) | View Count: (2758) | Return

Post a Comment

Latest Blogs
Subscribe to our Blog